Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics


Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)

Today's Latest Price: $58.00 USD

0.76 (-1.29%)

Updated Jul 9 4:00pm

Add HZNP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

HZNP Stock Summary

  • Horizon Therapeutics Public Ltd Co's market capitalization of $11,210,138,020 is ahead of 86.64% of US-listed equities.
  • Price to trailing twelve month operating cash flow for HZNP is currently 36.45, higher than 90.12% of US stocks with positive operating cash flow.
  • HZNP's price/sales ratio is 8.15; that's higher than the P/S ratio of 84.97% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be AKAM, TECH, MTCH, QUOT, and LNTH.
  • Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Daily Price Range
HZNP 52-Week Price Range

HZNP Stock Price Chart Technical Analysis Charts


HZNP Price/Volume Stats

Current price $58.00 52-week high $59.21
Prev. close $58.76 52-week low $22.81
Day low $56.89 Volume 1,905,287
Day high $59.21 Avg. volume 2,210,864
50-day MA $48.46 Dividend yield N/A
200-day MA $36.16 Market Cap 11.07B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio


Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$58.00$228.98300%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 75th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 301.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:

  • In the past 5.5 years, Horizon Therapeutics Public Ltd Co has a compound free cash flow growth rate of 1%; that's higher than 87.84% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 11% of the company's capital (with equity being the remaining amount). Approximately only 23.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 111 -- greater than 97.14% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%292%
1%296%
2%300%
3%304%
4%308%
5%311%

Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See LXRX, CI, MYL, AMEH, and CVS.


HZNP Latest News Stream


Event/TimeNews Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020

Horizon Therapeutics announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent J-code (J3241) for TEPEZZA.

Yahoo | July 9, 2020

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear's team has made significant progress and the company will receive an undisclosed milestone payment in accordance with the agreement with Horizon, which was executed in January 2019.

Yahoo | July 9, 2020

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Yahoo | July 8, 2020

Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 7, 2020

Horizon Therapeutics Looks Fairly Valued After Recent Run-Up

I first wrote about Horizon Therapeutics (HZNP) back in April and had initiated a full position in the company around the time of publication. Since then, Horizon reported its first-quarter results, and its stock has seen a substantial move. This article provides an update on what has changed for the...

Andy Jones on Seeking Alpha | July 3, 2020

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo 20.43%
3-mo N/A
6-mo 58.47%
1-year 147.12%
3-year 372.31%
5-year 61.38%
YTD 60.22%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%
2015 68.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.357 seconds.